Only One Submission at the EU level!
The joint clinical assessment of new health technologies is a valuable step to accelerate patients’ access to new health technologies, manufacturers’ access to the market and increase the efficiency of national HTA bodies’ assessments to make informed pricing and reimbursement decisions. The value of this joint work on HTA in the EU will be even more prominent when RWE is well established in the HTA processes.